Embolotherapy

Embolotherapy

Global Embolotherapy Market to Reach US$8.5 Billion by 2030

The global market for Embolotherapy estimated at US$5.1 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2023-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Support Devices segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 11.2% CAGR

The Embolotherapy market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Embolotherapy Market – Key Trends & Drivers Summarized

How Is Embolotherapy Revolutionizing Minimally Invasive Treatments?
Embolotherapy, a cutting-edge minimally invasive procedure, is redefining the landscape of medical treatments by effectively blocking blood flow to targeted areas, facilitating treatment for a variety of complex conditions such as cancer, vascular anomalies, and trauma-related bleeding. Initially employed to manage gastrointestinal bleeding and traumatic injuries, embolotherapy has evolved significantly, with applications expanding to fields like oncology and women’s health. In oncology, transarterial chemoembolization (TACE) and radioembolization are widely used for liver cancer treatment, depriving tumors of blood supply while delivering localized chemotherapy, minimizing damage to surrounding tissues. Similarly, uterine fibroid embolization has emerged as a preferred alternative to hysterectomy for women seeking non-surgical solutions, offering a less invasive, quicker recovery pathway. Beyond these areas, embolotherapy has become a popular choice in treating varicose veins, managing arterial malformations, and controlling bleeding in emergency trauma cases, providing healthcare providers with an efficient and often life-saving option in complex scenarios.

Beyond its primary applications, embolotherapy is recognized for its ability to manage high-risk patients who may not be ideal candidates for traditional surgical procedures. With its minimally invasive nature, the procedure reduces the overall risk of complications, shortens hospital stays, and decreases recovery time, factors that resonate with patient preferences for treatment. The procedure’s versatility allows it to be tailored to individual patients’ needs, whether in outpatient settings or within intensive care environments, which has broadened its appeal among healthcare providers. Additionally, in trauma cases, embolotherapy’s rapid deployment and precision in controlling internal bleeding can stabilize patients for further interventions. Given these benefits, embolotherapy continues to be a pivotal technique within interventional radiology and is projected to play an increasingly prominent role in managing complex medical conditions with a focus on patient-centered care.

What Technological Advancements Are Propelling Embolotherapy Forward?
Recent technological breakthroughs in imaging and catheter systems are propelling embolotherapy to new heights, making procedures safer, more precise, and increasingly effective across various clinical settings. Imaging advancements, such as high-definition fluoroscopy, MRI-guided intervention, and 3D imaging, allow healthcare providers to visualize target areas with remarkable detail, ensuring embolic agents are precisely deployed and minimizing impact on surrounding healthy tissue. Alongside these imaging enhancements, embolic materials themselves have evolved, with innovative options like drug-eluting beads and biodegradable microspheres offering dual benefits. These advanced materials block blood flow while simultaneously delivering localized drug therapy over time, enabling a more comprehensive approach to treating tumors and other complex conditions. The combination of imaging technology and advanced materials significantly enhances patient outcomes and broadens the potential applications of embolotherapy.

Another key development is the evolution of catheter technology, with new designs in micro and steerable catheters improving navigation within intricate vascular networks. This level of control is essential in procedures requiring pinpoint accuracy, such as those targeting tumors or abnormal blood vessels in sensitive areas like the brain. Additionally, robotic-assisted embolotherapy is an emerging trend, allowing clinicians to perform complex procedures with increased precision and reduced radiation exposure. The integration of artificial intelligence (AI) and machine learning in embolotherapy is also on the horizon, offering predictive insights into procedure outcomes, which can guide customized treatment plans. Collectively, these technological advancements are transforming embolotherapy into a highly precise, effective treatment option, meeting the evolving demands of modern healthcare and expanding the possibilities for minimally invasive interventions.

Why Are New End-Use Applications for Embolotherapy Emerging?
The scope of embolotherapy is rapidly expanding across a variety of therapeutic areas, largely due to its minimally invasive nature and effectiveness in treating hard-to-reach conditions. In oncology, for example, the procedure has proven effective not only for liver cancer but also for renal, prostate, and other types of tumors, offering patients less invasive alternatives to traditional surgery with fewer side effects. This technique is also becoming more common in trauma care, where its capacity to control internal bleeding makes it a critical tool in stabilizing patients before other surgical interventions. In women’s health, embolotherapy is gaining traction with procedures like uterine fibroid embolization, providing a non-surgical solution that appeals to patients seeking alternatives to hysterectomy, with quicker recovery times and less risk involved. These applications highlight embolotherapy’s potential to become a cornerstone treatment in multiple medical fields.

The versatility of embolotherapy extends to cardiovascular applications, where it is used to treat arteriovenous malformations (AVMs) and prevent aneurysms by regulating abnormal blood flow. As personalized medicine continues to grow, the procedure`s adaptability enables it to align with patient-specific needs, offering the possibility of combining embolic agents with targeted therapies. This personalized approach is expected to support further expansion in treatment areas, as clinicians can tailor procedures to individual patient profiles. Additionally, embolotherapy is seeing applications in gastrointestinal and urological treatments, as its precision and minimal invasiveness make it suitable for delicate structures. The broader adoption of this technique is not only improving patient outcomes but also enabling healthcare providers to offer advanced treatment options across an increasing array of medical conditions, reinforcing embolotherapy’s role as a critical tool in modern interventional medicine.

What’s Driving the Growth of the Global Embolotherapy Market?
The growth in the embolotherapy market is driven by several factors, primarily rooted in technological advancements, expanding end-use applications, and evolving healthcare preferences. Technological innovations such as high-definition imaging and sophisticated catheter designs have enhanced procedural precision, making embolotherapy a reliable choice across various therapeutic fields. This is particularly relevant in oncology, where the procedure’s minimally invasive nature and effectiveness in tumor targeting have led to increased adoption, especially in cases of liver and renal cancers. Furthermore, the development of drug-eluting and biodegradable embolic agents has broadened the scope of treatments, allowing for dual-action approaches that block blood supply and deliver localized drug therapy, a feature gaining traction in the oncology sector.

End-use expansion also plays a significant role in market growth, with embolotherapy being increasingly used in trauma care, women`s health, cardiovascular applications, and even emerging fields like urology and gastroenterology. Additionally, the trend towards patient-centered healthcare and the growing demand for minimally invasive procedures are further fueling adoption, as patients increasingly seek alternatives with shorter recovery times and lower complication risks. An aging population and rising incidence of chronic diseases, including cancer and vascular disorders, underpin the demand for embolotherapy as an effective, targeted intervention. Strategic collaborations between healthcare providers and manufacturers also support market growth by fostering innovation and making advanced solutions more accessible globally, especially in emerging markets. Together, these factors are positioning embolotherapy for sustained growth, driven by innovation, expanding applications, and a shift towards precision and minimally invasive treatments in modern healthcare.

Select Competitors (Total 42 Featured) -
  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Embolotherapy – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Incidence of Cancer and Vascular Disorders Expands the Addressable Market for Minimally Invasive Embolotherapy Solutions
Increasing Adoption of Minimally Invasive Medical Interventions Spurs Growth in Embolotherapy Techniques Across Key Healthcare Markets
Technological Advancements in Embolic Agents Improve Precision and Effectiveness, Driving Broader Adoption of Embolotherapy Solutions
Expanding Geriatric Population with Increased Risk of Vascular and Cancer-Related Conditions Propels Market Demand for Embolotherapy Procedures
Growing Awareness of Uterine Fibroid Embolization as a Non-Surgical Alternative to Hysterectomy Strengthens the Market for Womens Health Applications
Rising Prevalence of Arteriovenous Malformations (AVMs) Drives the Need for Specialized Embolotherapy Solutions to Treat Complex Vascular Malformations
Shift Toward Outpatient and Ambulatory Care Settings for Embolotherapy Procedures Expands Access and Drives Cost-Effective Healthcare Delivery
Growing Use of Embolization Techniques as Less Invasive Alternatives to Open Surgery in Trauma Cases Boosts Demand for Specialized Embolotherapy Solutions
Improved Biocompatibility of Next-Generation Embolic Materials Expands Usage in Multi-Therapeutic Applications, Including Oncology and Gynecology
Innovations in Catheter Technologies and Delivery Systems Improve Precision and Safety of Embolotherapy Procedures, Supporting Market Growth
Increased Adoption of Drug-Eluting Beads in Embolotherapy Enhances Efficacy in Cancer Treatment, Creating New Growth Opportunities in Oncology
Rising Global Healthcare Expenditures and Improved Access to Quality Care Drive Demand for Embolotherapy Solutions in Developed and Emerging Markets
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Embolic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Support Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Peripheral Vascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Urological & Nephrological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Embolotherapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
JAPAN
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
CHINA
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
EUROPE
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
FRANCE
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
GERMANY
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
UNITED KINGDOM
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Spain 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Russia 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
AUSTRALIA
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Australia 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
INDIA
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: India Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: India 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
LATIN AMERICA
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
MIDDLE EAST
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Iran 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Israel 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: UAE 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
AFRICA
Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Africa 16-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2014, 2024 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings